āshibio Emerges from Stealth with $40M to Advance Novel Therapies for Rare Genetic Diseases - Next Digital Health

A California-based biotechnology company, āshibio, has emerged from stealth with a combined seed and series A funding of $40M to accelerate the development of novel therapies for connective tissues and bone disorders. Founded in 2022 by Chief Executive Officer Pankaj Bhargava, M.D., the startup's latest round was spearheaded by MPM BioImpact, with participation from Agent āshibio will use the new capital to spur the development of novel therapies for severe genetic diseases such as fibrodysplasia ossificans progressiva (FOP).
read more..